NEW YORK (360Dx) – Grifols announced today that its antigen supply arrangement with OraSure Technologies has been extended.
Under the terms of the extended agreement, Grifols will supply antigens for OraSure's OraQuick HCV Rapid Antibody test, which is approved for qualitatively detecting hepatitis C virus antibodies in whole blood obtained through the use of a fingerstick or venipuncture. Additional terms were not disclosed.
Grifols also said today that it is in the process of building an $80 million biological manufacturing facility in the San Francisco Bay area. The firm is validating the facility and preparing to file a license with the US Food and Drug Administration certifying proper design, monitoring, and control of manufacturing processes and facilities.
Earlier this year, Hologic sold its stake in a blood screening business to Grifols — its partner in the business — for $1.85 billion.